Results 41 to 50 of about 123,607 (301)

Correlation between clinical and histopathologic diagnoses of potentially malignant oral lesions [PDF]

open access: yes, 2004
BACKGROUND: The serious nature of potentially malignant oral lesions (PMOL) demands that the final diagnosis be made on both clinical and histopathologic grounds.
Bokor-Bratić Marija   +2 more
core   +1 more source

What can we learn from treatments of oral lichen planus?

open access: yesFrontiers in Cellular and Infection Microbiology
Oral lichen planus (OLP), a T-lymphocyte-mediated disease of the oral mucosa, has a complex pathogenesis that involves a number of factors. The disease is characterized by recurrent episodes and requires continuous follow up, and there is no curative ...
Tingting Wu   +3 more
semanticscholar   +1 more source

Oral lichen planus and lichenoid lesions - challenges and pitfalls for the general dental practitioner

open access: yesBritish Dental Journal
Lichen planus is a chronic, mucocutaneous inflammatory condition which, due to its prevalence, will be familiar to the dental profession. However, diverse forms of presentation, important differential diagnosis, potential malignant change and monitoring ...
Rebecca Binnie   +3 more
semanticscholar   +1 more source

The Role of Serum Vitamin D Deficency in oral Lichen Planus Case Control Study

open access: yesDiyala Journal of Medicine, 2019
Background: Lichen planus is an autoimmune chronic inflammatory condition of unknown etiology affecting stratified squamous epithelial. The cell-mediated immunity has a role in both developing oral lichen planus, and immune system regulation, that’s why
Shaheen A Ahmed
doaj   +2 more sources

Successful treatment of erosive lichen planus with Upadacitinib complicated by oral squamous cell carcinoma

open access: yesSAGE Open Medical Case Reports, 2023
Erosive lichen planus is a chronic auto-inflammatory disease which affects the stratified squamous epithelia resulting in painful ulcerations of both the skin and mucosal surfaces, and has a known malignant potential.
Fiona M Landells   +4 more
doaj   +1 more source

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

open access: yes, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran   +2 more
core   +1 more source

Oral lichen planus: A disease or a spectrum of tissue reactions? Types, causes, diagnostic algorhythms, prognosis, management strategies.

open access: yesPeriodontology, 2019
Oral lichen planus and lichenoid lesions comprise a group of disorders of the oral mucosa that likely represent a common reaction pattern to 1 or more unknown antigens.
M. Carrozzo   +3 more
semanticscholar   +1 more source

Palmoplantar lichen planus [PDF]

open access: yesDermatology Online Journal, 2015
Palmoplantar lichen planus (PPLP) is an uncommon variant of lichen planus that affects the palms and soles. Clinical findings are varied although they have been conceptualized into two large groupings, an erythematous scaly pattern and a hyperkeratotic pattern. Histopathologic features are those of classic LP.
Rieder, Evan   +3 more
openaire   +4 more sources

Lichen planus following tetanus–diphtheria–acellular pertussis vaccination: A case report and review of the literature

open access: yesSAGE Open Medical Case Reports, 2018
Lichen planus is an inflammatory dermatosis with a prevalence of approximately 1%. Recent meta-analyses show that patients with hepatitis C virus have a 2.5- to 4.5-fold increased risk of developing lichen planus.
Heather C Rosengard   +3 more
doaj   +1 more source

Successful treatment of resistant plantar ulcerative lichen planus with tofacitinib: A case report and comprehensive review of the literature

open access: yesClinical Case Reports, 2023
Key Clinical Message Ulcerative lichen planus, a challenging variant of lichen planus, has limited response to traditional treatments. Tofacitinib, a JAK–STAT pathway inhibitor, shows promise in effectively treating these lesions.
Afsaneh Sadeghzadeh Bazargan   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy